With the highest professional and ethical standards, we commercialise therapies and technologies that uniquely fulfil the unmet medical needs of our community.
Specialised Therapeutics is an international biopharmaceutical company with strategic focus and expertise in Australia, New Zealand and South East Asia.
We partner with global pharmaceutical companies to champion their products from pre-registration through to full commercialisation, maintaining consistent, globally-aligned brand identities.
Every team member at Specialised Therapeutics contributes to this process, bringing extensive industry experience acquired in large international biopharmaceutical companies.
With expertise, we strategically navigate the complex regulatory and reimbursement pathways in these diverse markets.
As a result, we have a very successful track record commercialising specialised products.
Specialised Therapeutics is headquartered in Singapore, with representative offices in Melbourne and Auckland.
Carlo Montagner
Chief Executive Officer
Global medical and pharmaceutical executive Carlo Montagner founded Specialised Therapeutics in Australia in 2007 following a successful international career holding senior roles at some of the world’s largest pharmaceutical companies in the United States, Europe, China, Japan and Australia.
He is a former Vice President of Abraxis Bioscience Inc and a former Global Head of Bayer-Schering Oncology. He also served as a Global Team Leader of Sanofi-Aventis Oncology and a Hospital Business Unit Head of Aventis Australia, as well as serving as a Director of the Hospital Business Unit at Rhone-Poulenc Rorer.
Under Carlo’s leadership, Specialised Therapeutics has successfully commercialised nine speciality products spanning oncology, haematology, supportive care, emerging as the largest independent pharma company in Australia.
Carlo holds a Master of Science (Psychology) from RMIT University in Melbourne, Australia.
Bozena Zembrzuski
Co-Founder and Human Resources Director
Specialised Therapeutics Co-Founder and Human Resources Director, Bozena Zembrzuski, is a published molecular biologist and highly experienced pharmaceutical executive. She is a former Director of CNS Business Development with global pharmaceutical giant Novartis in the United States and has also held a range of senior management roles with Novartis Australia.
Bozena holds a Bachelor of Science (Hons) degree in Biological Sciences from Latrobe University in Melbourne, Australia.
ST People | Our team is comprised of experienced pharma executives who are passionate, driven and dedicated to making a difference. Click on the banner above to hear what makes Specialised Therapeutics special.
Specialised Therapeutics is committed to providing unrestricted access to innovative therapies for people with unmet medical needs. Our team makes this happen. How we work together and what we stand for makes us unique.
Working for Specialised Therapeutics provides the opportunity to work alongside industry professionals who have decades of experience in global pharmaceutical companies. We pride ourselves on our culture of inclusivity, our passion for pharma and compassion for our customers. We are a privately-held pharmaceutical company that has emerged as the largest independent pharmaceutical company in Australia. As a result, we are not limited by bureaucracy and our people can be creative in their roles and effect real change. We encourage all to 'own' their roles and show us how they shine.
At our new Australian headquarters in Melbourne, we are committed to providing a supportive and caring work environment, with a healthy and friendly culture that is supported by generous benefits. Our team is able to avail of flexible work and leave options, generous superannuation contributions, as well as health and lifestyle benefits.
For a confidential discussion at any time, please contact our Human Resources Manager Kate DeCarolis at kdecarolis@stbiopharma.com. We look forward to meeting you. In the meantime, please see below for current vacancies.
[video_lightbox_youtube video_id="g-rmX_oJv_s" width="1920" height="1080" anchor="https://stabiopharma.com/wpstabio/wp-content/uploads/2021/04/b-careers-employerofchoiceaward.jpg"]
Employment Opportunities
Senior Manager, Regulatory Affairs
Oncology / Haematology Medical Liaison (NSW)
Oncology / Haematology Medical Liaison (VIC)
Our History
- February 2007
- February 2008
- January 2009
- May 2009
- November 2010
- January 2012
- January 2014
- January 2014
- November 2014
- May 2015
- November 2015
- February 2016
- May 2017
- November 2017
- September 2018
- August 2018
- October 2019
- December 2019
- September 2020
- October 2020
- October 2020
- October 2021
- July 2022
- March 2023
- April 2023
- August 2023
- September 2023
- October 2023
- January 2024
-
-
ST – Abraxis Bioscience Partnership
ST - Abraxis Bioscience PartnershipST acquires exclusive Australian rights to market foundation product ABRAXANE® (nanoparticle-albumin bound paclitaxel) -
ST-Helsinn Healthcare Partnership
ST-Helsinn Healthcare PartnershipST partners with privately-owned Swiss pharma company Helsinn Healthcare, acquiring exclusive rights to anti-nausea drug ALOXI® (palonesetron) in Australia and NZ -
ABRAXANE® Reimbursed
ABRAXANE ReimbursedABRAXANE® (nanoparticle albumin-bound paclitaxel) reimbursed in Australia for metastatic breast cancer (mBc) -
-
Photonamic GmbH and co Partnership
Photonamic GmbH and co PartnershipST acquires exclusive rights to market brain tumour visualisation technology GLIOLAN® (animolivulenic acid hcl) in Australia, New Zealand -
Genomic Health Partnership
Genomic Health PartnershipST partners with US company Genomic Health to market the Oncotype DX Breast Recurrence Score® test -
Ariad Pharmaceuticals Partnership
Ariad Pharmaceuticals PartnershipUS-based Ariad Pharmaceuticals grants ST exclusive rights to market ICLUSIG® (ponatinib) in Australia, NZ -
ABRAXANE® reimbursed for metastatic pancreatic cancer (mPc)
ABRAXANE® reimbursed for metastatic pancreatic cancer (mPc)ST achieves a further PBS listing for ABRAXANE® in metastatic pancreatic cancer -
AKYNZEO® Acquired
AKYNZEO AcquiredST acquires AKYNZEO® (netupitant) under exclusive license from Helsinn Healthcare -
ICLUSIG® (ponatinib) Reimbursed for Chronic Myeloid Leukaemia (CML)
ICLUSIG (ponatinib) Reimbursed for Chronic Myeloid Leukaemia (CML)ST achieves PBS reimbursement for ICLUSIG® (ponatinib) in Australia -
ST PharmaMar SA Partnership
ST PharmaMar SA PartnershipST partners with Spanish company PharmaMar SA, acquiring exclusive rights to APLIDIN® (plitidepsin) in Australia, New Zealand and South East Asia -
ST acquires rights to anti-cancer compound ZEPZELCA® (lurbinectedin)
ST acquires rights to anti-cancer compound ZEPZELCA (lurbinectedin)ST signs a second major licensing deal with European pharmaceutical company PharmaMar. -
ST – Puma Biotechnology Partnership
ST – Puma Biotechnology PartnershipST partners with US-based Puma Biotechnology, acquiring exclusive rights to market NERLYNX® (neratinib) in Australia, NZ and South-East Asia -
ICLUSIG® achieves extended PBS listing
ICLUSIG achieves extended PBS listingST achieves further PBS reimbursement for ICLUSIG® in PH+ Acute Lymphoblastic Leukaemia (ALL) -
ST 10 Year Anniversary
ST 10 Year AnniversaryST celebrated its first decade in business, unveiling new Melbourne office in a ceremony led by Australian Federal Treasurer Josh Frydenberg MP. -
ST acquires rights to market YONDELIS® (trabectedin) in Australia, NZ and South East Asia
ST acquires rights to market YONDELIS (trabectedin) in Australia, NZ and South East AsiaST signs further licensing agreement with Spanish partner PharmaMar -
NERLYNX® (neratinib) approved in Singapore for extended adjuvant therapy in HER2+/HR+ breast cancer
ST achieves approval to market NERLYNX® (neratinib) in Singapore for the extended adjuvant treatment of adult patients with early-stage HER2 overexpressed/amplified breast cancer, to follow adjuvant trastuzumab-based therapy. -
ST wins PRIME Healthcare Award
ST wins PRIME Healthcare AwardST awarded a prestigious PRIME Healthcare Award for Excellence in Patient or Customer Support for NERLYNX® Patient Support Program -
ST-Deciphera Pharmaceuticals Partnership
ST-Deciphera Pharmaceuticals PartnershipST partners with US based Deciphera Pharmaceuticals, acquiring exclusive rights to market QINLOCK® (ripretinib) in Australia, NZ and South East Asia -
ST named 2020 Employer of Choice
ST named 2020 Employer of ChoiceST recognised as an Employer of Choice in prestigious national business awards. -
ST-Incyte Partnership Agreement
ST-Incyte Partnership AgreementST partners with Incyte Biosciences International Sàrl, the Swiss-based affiliate of Incyte (NASDAQ:INCY), to launch and distribute two new medicines for its haematology and oncology portfolios -
Vietnam Office Opened
Vietnam Office OpenedST established a representative office in Vietnam, to accommodate a growing regional presence. -
Thailand Office Opened
Thailand Office OpenedST established a representative office in Thailand, amid growing demand for specialist therapies in the region. -
ST – Akeso Inc. Partnership
ST – Akeso Inc. PartnershipSpecialised Therapeutics signs partnership agreement with Akeso Inc. and CTTQ-Akeso to commercialise new anti-PD1 antibody in Australia and Southeast Asia. -
ST – Treeway BV Partnership
ST – Treeway BV PartnershipSpecialised Therapeutics signs partnership agreement with Treeway BV to commercialise Edaravone in Australia and New Zealand. -
ST – World Orphan Drug Alliance (WODA) Partnership
ST – World Orphan Drug Alliance (WODA) PartnershipSpecialised Therapeutics joins the World Orphan Drug Alliance representing Australia, New Zealand and Southeast Asia (ANZSEA). -
ST – Canaria Bio Partnership
ST – Canaria Bio PartnershipSpecialised Therapeutics signed partnership agreement with Canaria Bio to commercialise Oregovomab in Australia, New Zealand and select Southeast Asia countries. -
ST – Ascendis Pharma Partnership
ST – Ascendis Pharma PartnershipSpecialised Therapeutics Signs Exclusive Agreement With Ascendis Pharma For Three Endocrinology Therapies